Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin

Figures & data

Table 1 Phase II studies of GO monotherapy in relapsed and refractory acute myeloid leukemia

Ref.	Number of patients	Median age (range)	GO dose	CR/CRp	Median OS (months)	RFS (months)
Larson et al^Citation34	277	61 (20–87)	9 mg/m^2 on days 1 and 14	13/13	4.9 (all patients) 12.2 (CR patients) 12.9 (CRp patients)	5.2 (all patients) 6.4 (CR patients) 4.5 (CRp patients)
Taksin et al^Citation56	57	64 (22–80)	3 mg/m^2 on days 1, 4, and 7	26/7	8.4 (all patients)	11 (all patients)
Piccaluga et al^Citation53	24	63 (20–75)	Either 9 mg/m^2 or 6 mg/m^2 for 3 days, at least 14 days apart	3/2	2 (all patients)	–

Abbreviations: GO, gemtuzumab ozogamicin; CR, complete remission; CRp, complete remission with incomplete platelet recovery; OS, overall survival; RFS, relapse-free survival.

Table 2 Phase I and II studies of GO combination chemotherapy in relapsed and refractory acute myeloid leukemia

Ref.	Number of patients	Median age (range)	Other chemotherapy	GO dose	CR/CRp	Median OS (months)
Tsimberidou et al^Citation36	32	53 (18–78)	Fludarabine, Ara-C, cyclosporine	4.5 mg/m^2 on day 1	9/2	5.3
Chevallier et al^Citation40	62	55.5 (16–71)	Mitoxantrone, Ara-C	9 mg/m^2 on day 4	31/8	9.5
Stone et al^Citation37	44	64 (55–69)	HiDAC	9 mg/m^2 on day 7	7/2	Not yet reported
Cortes et al^Citation54	17	55 (23–75)	Topotecan, cytarabine	9 mg/m^2 on day 1	2/0	8.2 weeks
Alvarado et al^Citation55	14	61 (34–74)	Idarabucin, cytarabine	6 mg/m^2 on days 1 and 15	3/3	2
Fianchi et al^Citation39	53	69 (65–77)	Cytarabine, G-CSF	6 mg/m^2 on day 9	23/1	9

Abbreviations: GO, gemtuzumab ozogamicin; CR, complete remission; CRp, complete remission with incomplete platelet recovery; OS, overall survival; RFS, relapse-free survival.

LarsonRASieversELStadtmauerEAFinal report of efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first recurrenceCancer20051041442145216116598

 PubMed Web of Science ®Google Scholar

TaksinALLegrandORaffouxEde RevelTHigh efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alpha groupLeukemia200721667117051246

 PubMed Web of Science ®Google Scholar

PiccalugaPPMartinelliGRondoniMGemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomasLeuk Lymphoma20044591791179515223637

 PubMed Web of Science ®Google Scholar

TsimberidouACortesJThomasDGemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaLeuk Res20032789389712860008

 PubMed Web of Science ®Google Scholar

ChevallierPDelaunayJTurlurePLong-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaJ Clin Oncol200826325192519718854573

 PubMed Web of Science ®Google Scholar

StoneRMMoserBSchulmanPA dose escalation and phase II study of Gemtuzumab Ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients with refractory or relapsed acute myeloid leukemia; CALGB 19902Blood2004104 Abstr 873.

 Web of Science ®Google Scholar

CortesJTsimberidouAAlvarezRMylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemiaCancer Chemother Pharmacol20025049750012451477

 PubMed Web of Science ®Google Scholar

AlvaradoYTsimberidouAKantarjianHPilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemiaCancer Chemother Pharmacol200351879012497211

 PubMed Web of Science ®Google Scholar

FianchiLPaganoLLeoniFGemtuzumab, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemiaAnn Oncol20081912813417906298

 PubMed Web of Science ®Google Scholar